Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1A | P54750 | 7/20 | 0.81 |
| ▸ | PDE4A | P27815 | 12/20 | 0.56 |
| ▸ | PDE1B | Q01064 | 3/20 | 0.55 |
| ▸ | PDE2A | O00408 | 2/20 | 0.44 |
| ▸ | PDE8A | O60658 | 2/20 | 0.44 |
| ▸ | PDE5A | O76074 | 2/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.44 |
| ▸ | PDE11A | Q9HCR9 | 2/20 | 0.44 |
| ▸ | PDE7B | Q9NP56 | 2/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.44 |
| ▸ | PDE9A | O76083 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17508445 | 0.91 | PDE1A (0.79) | PDE1APDE4APDE1BPDE2APDE8A | |
| SCHEMBL31571927 | 0.91 | PDE1A (0.78) | PDE1APDE4APDE1BPDE2APDE8A | |
| SCHEMBL31571924 | 0.91 | PDE1A (0.78) | PDE1APDE4APDE1BPDE2APDE8A | |
| SCHEMBL31571922 | 0.91 | PDE1A (0.78) | PDE1APDE4APDE1BPDE2APDE8A | |
| SCHEMBL16036074 | 0.90 | PDE1A (1.00) | PDE1APDE4APDE1BPDE2APDE8A | |
| SCHEMBL31571925 | 0.90 | PDE1A (0.79) | PDE1APDE4APDE1BPDE2APDE8A | |
| SCHEMBL31571929 | 0.90 | PDE1A (0.79) | PDE1APDE4APDE1BPDE2APDE8A | |
| SCHEMBL17508452 | 0.89 | PDE1A (0.76) | PDE1APDE4APDE1B | |
| SCHEMBL16088170 | 0.89 | PDE1A (0.86) | PDE1APDE4APDE1BPDE2APDE8A | |
| SCHEMBL16036012 | 0.89 | PDE1A (1.00) | PDE1APDE4APDE1BPDE2APDE8A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3725789-B1 | 7,8-DIHYDRO-[2H]-IMIDAZO-[1,2-A]PYRAZOLO[4,3-E]PYRIMIDIN-4(5H)-ONE DERIVATIVES AS PHOSPHODIESTERASE 1 (PDE1) INHIBITORS FOR TREATING DISEASES, DISORDERS OR INJURIES OF THE CENTRAL NERVOUS SYSTEM (CNS) | INTRA CELLULAR THERAPIES INC (US) | 2022-03-09 | — | — | EP | disclosed |
| CN-107106563-B | Compounds and methods | 细胞内治疗公司 | 2021-05-25 | — | — | CN | disclosed |
| EP-3193878-B1 | 7,8-DIHYDRO-[2H]-IMIDAZO-[1,2-A]PYRAZOLO[4,3-E]PYRIMIDIN-4(5H)-ONE DERIVATIVES AS PHOSPHODIESTERASE 1 (PDE1) INHIBITORS FOR TREATING DISEASES, DISORDERS OR INJURIES OF THE CENTRAL NERVOUS SYSTEM (CNS) | INTRA CELLULAR THERAPIES INC (US) | 2021-01-06 | — | — | EP | disclosed |
| EP-3725789-A1 | 7,8-DIHYDRO-[2H]-IMIDAZO-[1,2-A]PYRAZOLO[4,3-E]PYRIMIDIN-4(5H)-ONE DERIVATIVES AS PHOSPHODIESTERASE 1 (PDE1) INHIBITORS FOR TREATING DISEASES, DISORDERS OR INJURIES OF THE CENTRAL NERVOUS SYSTEM (CNS) | Intra-Cellular Therapies, Inc. (US) | 2020-10-21 | — | — | EP | disclosed |
| US-20190144460-A1 | COMPOUNDS AND METHODS | INTRA-CELLULAR THERAPIES, INC. (US) | 2019-05-16 | — | — | US | disclosed |
| US-20190144460-A1 | COMPOUNDS AND METHODS | INTRA-CELLULAR THERAPIES, INC. (US) | 2019-05-16 | — | — | US | disclosed |
| US-10150774-B2 | Compounds and methods | INTRA-CELLULAR THERAPIES, INC. (US) | 2018-12-11 | — | — | US | disclosed |
| US-20170291904-A1 | COMPOUNDS AND METHODS | INTRA-CELLULAR THERAPIES, INC. | 2017-10-12 | — | — | US | disclosed |
| US-20170291904-A1 | COMPOUNDS AND METHODS | INTRA-CELLULAR THERAPIES, INC. | 2017-10-12 | — | — | US | disclosed |
| US-20170291904-A1 | COMPOUNDS AND METHODS | INTRA-CELLULAR THERAPIES, INC. | 2017-10-12 | — | — | US | disclosed |
| EP-3193878-A1 | COMPOUNDS AND METHODS | Intra-Cellular Therapies, Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| WO-2016044667-A1 | COMPOUNDS AND METHODS | INTRA-CELLULAR THERAPIES, INC. (US) | 2016-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10150774-B2 | Compounds and methods | BDNF, PYGB, SMPD1 | PDE1A 26/4885PDE4A 30/4885PDE1B 31/4885 |
| US-20170291904-A1 | COMPOUNDS AND METHODS | BDNF, PYGB, SMPD1 | PDE1A 26/4885PDE4A 30/4885PDE1B 31/4885 |
| US-20190144460-A1 | COMPOUNDS AND METHODS | BDNF, PYGB, SMPD1 | PDE1A 26/4885PDE4A 30/4885PDE1B 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.